Efficacy and safety of chemotherapy plus immunotherapy in unresectable stage III–IV non-small cell lung cancer, with analysis of the additional role of anti-angiogenic agents
Purpose Chemo-immunotherapy has demonstrated significant survival benefits in non-small cell lung cancer. However, real-world data on its effectiveness and safety in patients with unresectable stage III–IV disease remain insufficient. Furthermore, whether the addition of anti-angiogenic agents provides additional benef...